Borosil Scientific Q2 Profit Rises 86% as Goel Loss Narrows
Key highlights
- Consolidated PAT rose 86.3% to Rs 5.3 crore in Q2FY27, while consolidated EBITDA increased 29.4% to Rs 11.0 crore.
- Goel Glass Works Scientific Limited increased quarterly sales 28.7% to Rs 11.2 crore and narrowed its loss before tax to Rs 1.1 crore.
- Standalone PAT fell 16.9% to Rs 6.2 crore as standalone EBITDA margin declined to 11.3% from 13.1%.
- BSL plans Rs 60 crore of glassware expansion by March 2027 and a borosilicate tubing furnace costing up to Rs 70 crore by March 2028.
powered by IRIS

Borosil Scientific (BSL) reported consolidated profit after tax of Rs 5.3 crore in Q2FY27, up 86.3% from Rs 2.9 crore a year earlier, despite a 16.9% fall in standalone profit. BSL attributed the consolidated improvement to stronger sales and operations at Goel Glass Works Scientific Limited, where loss before tax narrowed to Rs 1.1 crore from Rs 4.8 crore.
Know Borosil Scientific inside out
Results, valuation, peers and who's buying, in one view.
Why did BSL's Q2FY27 consolidated profit rise?
BSL's consolidated profit rose because improved sales and operating performance at Goel Glass Works Scientific Limited offset higher input costs in its standalone business. Consolidated profit after tax, or PAT, increased to Rs 5.3 crore in Q2FY27 from Rs 2.9 crore in Q2FY26, while profit before tax rose 49.5% to Rs 7.7 crore from Rs 5.1 crore.
Goel Glass Works Scientific Limited was the specific contributor identified by BSL. The subsidiary's quarterly sales rose 28.7% year on year to Rs 11.2 crore from Rs 8.7 crore, while its loss before tax narrowed by Rs 3.7 crore to Rs 1.1 crore from Rs 4.8 crore.
Consolidated net sales increased 7.5% to Rs 115.0 crore in Q2FY27 from Rs 106.9 crore in Q2FY26. Earnings before interest, tax, depreciation and amortisation, or EBITDA, grew 29.4% to Rs 11.0 crore from Rs 8.5 crore, and the EBITDA margin rose to 9.6% from 8.0%.
How did BSL's standalone results differ from consolidated results?
BSL's standalone profitability declined in Q2FY27 while consolidated profitability increased, because higher input costs linked to geopolitical tensions in the Middle East affected the standalone business. Standalone PAT fell to Rs 6.2 crore from Rs 7.5 crore, and standalone EBITDA declined 9.7% to Rs 11.7 crore from Rs 13.0 crore.
Standalone net sales still rose 4.7% to Rs 104.2 crore from Rs 99.5 crore, but operating earnings did not follow sales higher. Standalone EBITDA margin declined to 11.3% from 13.1%, while earnings before interest and tax, or EBIT, fell 19.3% to Rs 6.9 crore from Rs 8.6 crore.
The sequential comparison showed a similar distinction between revenue and operating profit. Standalone sales increased to Rs 104.2 crore in Q2FY27 from Rs 99.9 crore in Q1FY27, while EBITDA was Rs 11.7 crore against Rs 11.5 crore; consolidated sales rose to Rs 115.0 crore from Rs 106.8 crore and consolidated EBITDA increased to Rs 11.0 crore from Rs 8.7 crore.
Management said standalone profitability is expected to improve as the Middle East situation stabilises and said it is taking initiatives to reduce the impact. The presentation gives neither a value nor timetable for those initiatives, and notes that Q2FY27 EBITDA and EBIT exclude investment income of Rs 2.1 crore.
Got a follow-up? Ask IRIS
Which BSL segments generated sales growth in Q2FY27?
BSL's Process System and Primary Pharma Packaging categories delivered the fastest reported year-on-year growth in Q2FY27, while Consumer Glassware declined. Process System sales rose 64.6% to Rs 12.4 crore from Rs 7.6 crore, and Primary Pharma Packaging increased 21.4% to Rs 21.0 crore from Rs 17.3 crore.
The Scientific segment grew 8.3% to Rs 79.1 crore from Rs 73.0 crore. Within it, Lab Consumables rose 2.2% to Rs 55.3 crore, Lab Equipments remained at Rs 11.3 crore, and the larger increase in Process System provided much of the segment's growth.
Consumer Glassware sales fell 10.2% to Rs 15.0 crore from Rs 16.7 crore. For H1FY27, consolidated sales were Rs 221.7 crore, up 9.3% from Rs 202.9 crore, with Primary Pharma Packaging up 26.6% to Rs 44.0 crore and Consumer Glassware down 3.5% to Rs 30.3 crore.
BSL changed its internal reporting structure in the quarter ended September 30, 2026, so that its chief operating decision maker reviews Consumer Glassware separately. Under Indian Accounting Standard 108, the company restated earlier periods into Scientific, Primary Pharma Packaging and Consumer Glassware, and said excluding the Ind AS 115 effect, H1FY27 growth was 6.3% for Lab Consumables and 10.7% across product categories.
What expansion projects has BSL disclosed?
BSL has proposed expanding glassware capacity from about 15 lakh units a year to about 108 lakh units a year, with commercial production expected in March 2027. The project has estimated capital expenditure of Rs 60 crore, proposed funding through internal accruals and borrowings, and existing utilisation of about 87%.
Management said the capacity is intended to meet increasing demand from Borosil Limited and expected laboratory glassware expansion. BSL also said it may apply for eligible subsidy support under the Viksit Gujarat Industrial Policy 2026, subject to availability and eligibility.
BSL has separately planned a greenfield borosilicate 3.3 glass tubing furnace with installed capacity of about 20 metric tonnes a day. The project has planned capital expenditure of up to Rs 70 crore, expected commercial production by March 31, 2028, and proposed funding from internal accruals and/or borrowings; the tubing is primarily intended for captive consumption, with surplus potentially sold externally.
Conclusion
BSL's Q2FY27 results show that consolidated earnings growth came from 7.5% sales growth, a 160-basis-point increase in consolidated EBITDA margin to 9.6%, and a smaller loss at Goel Glass Works Scientific Limited. This contrasted with the standalone result, where PAT fell 16.9% and EBITDA margin declined 180 basis points as higher input costs affected profitability.
The next points to watch are the stabilisation of Middle East-linked input costs and BSL's stated measures to reduce their effect. The company expects its Rs 60 crore glassware project to begin commercial production in March 2027 and its borosilicate tubing furnace, costing up to Rs 70 crore, by March 31, 2028.


